Conference Coverage
Conference Coverage
Pregnant Women With Lymphoma Can Have Good Outcomes
Major Finding: Among women with lymphomas diagnosed during pregnancy, the 3-year progression-free survival rates were 76% in women who underwent...
Conference Coverage
IGF-I Doesn't Predict Late Complications in Childhood Cancer Survivors
Major Finding: Among childhood cancer survivors who had low IGF-I levels and received growth hormone stimulation, IGF-I z scores did not did not...
Conference Coverage
Rivaroxaban VTE Prophylaxis Works in Real-World Practice
Major Finding: The in-hospital incidence of symptomatic VTE was 2.4% with rivaroxaban, 3.9% with low molecular weight heparin, and 5.5% with...
Conference Coverage
NAFLD in Adolescence Predictable in Young Children
Major Finding: Thirteen percent of children developed NAFLD by age 17 years.
Conference Coverage
NAFLD Common in Teenage Girls with PCOS
Major Finding: A total of 43% of teenage girls with polycystic ovary syndrome have concomitant nonalcoholic fatty liver disease.Data Source: The...
Conference Coverage
Most Febrile Seizures Don't Lead to Epilepsy
Major Finding: Children with febrile seizures were almost 10 times more likely to develop epilepsy than were their peers, yet their standardized...
Conference Coverage
Iron Deficiency Anemia 'Unintended Consequence' of Gastric Bypass
Major Finding: Gastric bypass surgery was determined to be the cause of iron deficiency anemia in 24% of cases.Data Source: A study of 130...
Conference Coverage
Urinary Dysfunction Stands Out on Retigabine's Safety Profile
Major Finding: Urinary hesitation occurred in 3.1% of the entire phase II/III study group, and urinary retention occurred in 1.9%.Data Source:...
Conference Coverage
RA, Periodontal Disease May Be Bi-Directional
Conference Coverage
Vitamin D Deficiency/Breast Cancer Link Questioned
Major Finding: Serum vitamin D levels measured before diagnosis of breast cancer showed no significant association with breast cancer risk.Data...
Conference Coverage
Raltegravir-Based HIV Therapy Bests Efavirenz-Based Treatment
Major Finding: At 192 weeks, 214 of 280 HIV-1–infected patients randomized to raltegravir-based treatment (76%) met the viral load target of less...